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Elevated levels of plasma homocysteine, an independent risk factor and a strong
predictor of mortality in patients with coronary artery disease (CAD), can result from
nutritional deficiencies or genetic errors, including methylenetetrahydrofolate
reductase (MTHFR) C677T and A1298C polymorphisms. The contribution of these
polymorphisms in the development of CAD remains controversial. We analysed the
impact of MTHFR C677T and A1298C on fasting homocysteine and CAD in 298 CAD
patients proved by angiography and 510 control subjects from the Island of Madeira
(Portugal). After adjustment for other risk factors, plasma homocysteine remained
independently correlated with CAD. Serum homocysteine was significantly higher in
individuals with 677TT and 1298AA genotypes. There was no difference in the
distribution of MTHFR677 genotypes between cases and controls but a significant
increase in 1298AA prevalence was found in CAD patients. In spite of the clear effect
of C677T mutation on elevated homocysteine levels we only found an association
between 1298AA genotype and CAD in this population. The simultaneous presence of
677CT and 1298AA genotypes provides a significant risk of developing the disease,
while the 1298AC genotype, combined with 677CC, shows a significant trend towards
a decrease in CAD occurrence. The data shows an independent association betweenKEYWORDS
MTHFR;
Homocysteine;
Gene polymorphisms;
Coronary artery diseaseetics Laboratory, University of Madeira—Campus of Penteada, 9000-390 Funchal, Portugal.
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649MTHFR gene, homocysteine and CAD in Portugalelevated levels of homocysteine and CAD. Both MTHFR polymorphisms are associated
with increased fasting homocysteine (677TT and 1298AA genotypes), but only the
1298AA variant shows an increased prevalence in CAD group. Odds ratio seem to
indicate that individuals with the MTHFR 1298AA genotype and the 677CT/1298AA
compound genotype had a 1.6-fold increased risk for developing CAD suggesting a
possible association of MTHFR polymorphisms with the risk of CAD in Madeira
population.
© 2008 Elsevier Ltd. All rights reserved.Introduction
Fasting plasma homocysteine (Hcy) is a graded and
independent risk factor for coronary and other forms
of vascular disease [1–3]. Individual variation in Hcy
levels is related to several biological traits and is
strongly influenced by dietary habits, specifically
the intake of vitamins such as folate, vitamin B6 and
B12 [4]. Deficiencies in these vitamins, which are
essential coenzymes in homocysteine metabolism,
elevate plasma Hcy levels [5,6].
The methylation of homocysteine into methionine
is catalysed by the 5,10-methylenetetrahydrofolate
reductase (MTHFR) enzyme. Gene polymorphisms of
those enzymes involved in the Hcy metabolism,
particularly MTHFR, are well known and some are
the cause of mild increases in the levels of circu-
lating Hcy [7]. MTHFR gene polymorphisms C677T
and A1298C are common in human populations.
The C677T mutation (Alanine→Valine), resulting
in a thermolabile enzyme, is associated with mild
hyperhomocysteinemia and possibly with an in-
creased risk of CAD [8]. Some studies showed
positive associations [8–10] between MTHFR TT
homozygotes and risk of CAD, but other studies
have failed to demonstrate such a relationship [11–
13]. A recent meta-analysis concluded that indivi-
duals with the 677TT genotype had 16% higher
odds of CAD compared with individuals with the CC
genotype [14]. However, the results were hetero-
geneous, being significant in European populations
but non significant in North Americans, probably
as a consequence of the interaction between the
MTHFR polymorphism and folate status. The ap-
parent discrepancy between the risk attributable
to plasma Hcy and to the MTHFR C677T polymor-
phism may therefore be partly explained by the
complexity of the nutritional/genetic interaction
underlying the homocysteine metabolism [4]. In
brief, most prospective and retrospective studies
to date have indicated that mildly elevated plas-
ma Hcy is independently associated with CAD, and
that the MTHFR TT genotype is associated with
elevated Hcy. Paradoxically, most studies have notdemonstrated an association between CAD and TT
genotype.
Another polymorphism in MTHFR, 1298 A→Cmuta-
tion, results in an amino acid change of glutamate to
alanine in the regulatory C-terminal domain of the
enzyme [15]. In vitro, 1298C carriers showed a de-
creased enzyme activity, suggesting a functional
importance of the A1298C polymorphism although
through an unknown molecular mechanism [16].
Nevertheless, it appears that the A1298C polymorph-
ism alone does not significantly affect plasma Hcy but
may be determinant when combined with the 677T
variant [17].
Themain focus of the present study was to analyse
two markers belonging to the MTHFR gene, alone or
combined in haplotypes and clarify their potential
association with Hcy values and the presence of CAD
related conditions in a series of patients who under-
went coronary angiography.
Materials and methods
The total population of this study consisted of 808 Caucasian
individuals (aged between 18 and 70 years old) divided in
two groups; 510 subjects without a history of cardiovascular
disease (CAD), randomly selected from the electoral rows, who
participated as controls, plus 298 individuals recruited from
patients admitted to the Cardiology Care Unit of the main
hospital of Funchal (Hospital Central do Funchal, Madeira Island,
Portugal). All subjects gave informed consent to participate in
this research and the work was approved by the hospital ethics
committee. Recruitment of cases satisfied the following criteria:
stable coronary disease suggested by clinical analysis and proved
by a coronary angiographic exam (“we considered the existence
of a significant coronary lesion when over 50% of the left main or
over 75% of one or more of the major coronary arteries and their
branches, right coronary artery, left anterior descendent or
circumflex were obstructed.”) and occurrence of acute myocar-
dial infarction. To inquire the family clinical history, the subjects
were questioned about the existence of diabetes, essential
hypertension or coronary disease in first degree relatives
(parents and brothers or sisters). Premature death related to
any of these causes was also registered. Cases and controls filled
in a questionnaire about their personal histories (age, sex,
essential hypertension, diabetes mellitus, smoking habits, dyslipi-
daemia, overweight, sedentary habits, alcohol ingestion and family
history and provided blood samples for genotype analysis and bio-
chemical measurements.
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Genomic DNAwas extracted from an 80 µl aliquot of whole blood
collected in EDTA using standard phenol/chloroform methodol-
ogies with ethanol precipitation. The extracted DNA was stored
at −20 °C until analysis.
MTHFR C677T polymorphism was assayed by PCR amplifica-
tion using primers and conditions previously described [18].
10 µl of PCR product was digested overnight at 37 °C with 1
unit of HinfI in a final volume of 20 µl according to the manu-
facturers' instructions (New England Biolabs). This reaction
yielded fragments of 198 base pairs in the presence of the C
allele, and 175 and 23 base pairs in the presence of the Tallele.
Digestion results were submitted to electrophoresis in T9C5
polyacrilamide gels and visualised after silver staining. The
A1298C mutation of the MTHFR gene was amplified by PCR as
previously described [19], sequenced using BigDye terminator
kit (Applied Biosystems) and visualised in an ABIPrism 310 Auto-
matic Sequencer.
Fasting plasma homocysteine was determined by HPLC.
Serum total cholesterol, triglycerides, HDL cholesterol andTable 1 Baseline characteristic, clinical data of convention
control subjects [adapted [26]]
Controls
N 510
Gender (Male/Female, %) 57.84/42.
Age (years, mean) 47.47±12
Sedentarism (%) 61.96
Alcohol (g/day) 35.32±81
Smoking habit (%) 26.86
Familiar CAD history (%) 12.16
Systolic blood pressure (mm Hg) 127.54±1
Diastolic blood pressure (mm Hg) 75.83±10
Arterial hypertension a (%) 22.35
Cardiac frequency 72.04±8.
PWV (m/s) 8.80±1.8
Body mass index (kg/m2) 26.41
Glycaemia (mg/dl) 97.96±24
Diabetes mellitus b (%) 3.14
Total cholesterol (mg/dl) 217.72±4
HDL (mg/dl) 57.15±17
LDL (mg/dl) 114.70±3
Triglycerides (mg/dl) 130.73±8
Dyslipidaemia c (%) 11.76
APO B (mg/dl) 103.52±2
Homocysteine (mmol/l) 9.72±3.5
Fibrinogen (mg/dl) 274.78±6
MTHFR C677T CC 262 (51.3
CT 200 (39.2
TT 48 (9.41%
MTHFR A1298C AA 222 (43.5
AC 259 (50.7
CC 29 (5.69%
⁎Pb0.05, ⁎⁎Pb0.005, ⁎⁎⁎Pb0.0001, NS not significant PN0.05.
PWV, pulse wave velocity; HDL high-density lipoprotein; LDL low-de
a medicated against hypertension/arterial tension≥139/89 mm H
b medicated with anti-diabetic drugs/glycaemia≥126 mg/dl.
c total cholesterol≤200 mg/dl, triglycerides≥150 mg/dl, LDL≥13
d χ2 (2df) was performed for the overall distribution of genotypesLDL cholesterol were measured using a Hitachi 911 Automatic
Analyser.
Statistical analyses
Basic genetic parameters such as allele and genotype frequen-
cies at each locus, proportion of individual heterozygous
samples (direct count heterozygosity, Ho, as well as the unbiased
estimate, He) and population differentiation were calculated
using Genepop v3.1d [20] and Arlequin [21]. Haplotype
frequencies were calculated using the PHASE 2.0 software
[22]. The overall genetic diversity (HT), within each group
diversity (HS) and the amount among groups (DST) were also
calculated. Deviation from Hardy–Weinberg equilibrium per
population and locus was calculated according to FIS estimator
[23]. The significance value of FIS was evaluated through a
bootstrap technique based on random permutation of the
original dataset, as implemented in FSTAT v.2.9.3 [24]. This
program implements a Bonferroni correction for all significance
levels [25]. Within all groups of subjects, distribution of allele
and genotype frequencies and their differences were calculatedal risk factors and distribution of genotypes in cases and
Cases P
298
16 78.86/31.82 ⁎⁎⁎
.55 54.96±10.40 ⁎⁎⁎
58.39 NS
.94 56.80±87.01 ⁎⁎⁎
38.93 ⁎⁎⁎
56.04 ⁎⁎⁎
7.43 134.63±20.43 ⁎⁎⁎
.69 79.10±10.46 ⁎⁎⁎
58.72 ⁎⁎⁎
62 68.90±12.75 ⁎⁎⁎
9 10.26±2.13 ⁎⁎⁎
27.80 ⁎⁎⁎
.47 119.94±50.60 ⁎⁎⁎
23.15 ⁎⁎⁎
4.73 205.39±48.14 ⁎⁎
.04 39.74±9.75 ⁎⁎⁎
7.27 119.02±44.08 NS
5.71 192.97±142.96 ⁎⁎⁎
70.81 ⁎⁎⁎
8.37 103.47±27.53 NS
8 11.70±3.72 ⁎⁎⁎
1.18 335.95±95.85 ⁎⁎⁎
7%) 130 (43.62) NSd
2%) 136 (45.53%)
) 32 (10.75%)
3%) 158 (53.02%) ⁎ d
8%) 123 (41.28%)
) 17 (5.70%)
nsity lipoprotein; APO B apolipoprotein B.
g.
0 mg/dl and HDL≤40 mg/dl.
among cases and controls.
Table 2 Allele frequencies and population parameters related to MTHFR polymorphisms
Alleles Control group Cases Fis Control group/cases Ho Hs Gis
MTHFR677 C 0.710 0.665 0.049/−0.022 0.424 0.430 0.012
T 0.290 0.335
MTHFR1298 A 0.689 0.747 −0.185⁎⁎/0.052 0.460 0.409 −0.126
C 0.311 0.253
Overall −0.040/−0.070 0.442 0.419 −0.055
⁎⁎Pb0.005.
Gis is an estimator of Fis based on Nei's (1987) statistic [27] and is estimated for each locus and overall. Ho is the observed proportion
of heterozygotes, Hs is the within sample gene diversity.
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applying Fisher's exact test adjusted for multiple comparisons of
associated genotypes. To test the significance of association
between genotypes at pairs of loci in each sample we used a log-
likelihood ratio G-statistic as implemented in Genepop. The
relative odds ratio (OR) and 95% confidence interval of relative
risk of CAD for any of the genetic polymorphisms and
biochemical and behaviour markers, was assayed by multiple
logistic regressions using the SPSS package.Table 3 Variation of homocysteine concentrations among c
and haplotypes
Homo
Cases
Allele
MTHFR677 C/T 11.53
MTHFR1298 A/C 11.74
Genotype
MTHFR677 CC/nCC 11.25
CT/nCT 11.80
TT/nTT 13.12
MTHFR1298 AA/nAA 12.35
AC/nAC 10.94
CC/nCC 11.17
Haplotype
MTHFR 677-1298 C–A/nC–A 11.56
T–A/nT–A 12.08
C–C/nC–C 11.02
T–C/nT–C 10.63
Combined genotype
MTHFR 677-1298 CC–AA/nCC–AA 11.35
CC–AC/nCC–AC 11.14
CC–CC/nCC–CC 11.44
CT–AA/nCT–AA 12.44
CT–AC/nCT–AC 10.82
CT–CC a/nCT–CC –
TT–AA/nTT–AA 13.79
TT–AC/nTT–AC 9.54±
TT–CC b/nTT–CC –
The values obtained for each single genotype, haplotype and comb
genotypes, haplotypes and combined haplotypes found in our popu
compared between individuals carrying CC genotype and those car
Values presentation: mean±SD; ⁎Pb0.05, ⁎⁎Pb0.005, ⁎⁎⁎Pb0.0001.
a Only one control subject and one patient presented the CT–CC
b Combined genotype TT–CC was not observed.Results
The baseline demographic and clinical characteristics of the
study population are listed in Table 1. As expected, both the
control and patient groups show differences in the biochemical
markers and other conventional risk factors analysed (Table 1).
Systolic and diastolic blood pressure, dyslipidaemia, arterial
hypertension, diabetes mellitus, triglycerides and fibrinogen
were significantly higher in CAD patients then in controls.ases and controls according to MTHFR alleles, genotypes
cysteine (mmol/l)
Controls
±3.43/13.12±5.45⁎ 9.57±3.03/11.20±6.78⁎⁎⁎
±3.76/11.17±2.96 9.73±3.64/9.70±2.26
±2.82/12.05±4.26⁎⁎ 9.42±2.78/10.05±4.24⁎⁎
±3.92/11.62±3.56 9.77±3.33/9.70±3.74
±5.45/11.53±3.43⁎ 11.20±9.73/9.57±3.03⁎⁎⁎
±4.25/10.97±2.85⁎ 9.99±4.17/9.53±3.03⁎
±2.84/12.24±4.15⁎⁎ 9.50±3.11/9.95±3.99
±2.96/11.74±3.76 9.70±2.26/9.73±3.64
±3.46/12.44±4.80 9.57±3.08/10.63±5.55⁎⁎
±4.26/11.22±2.84⁎⁎ 10.04±4.25/9.44±2.79⁎⁎
±2.87/12.27±4.22⁎ 9.43±2.87/10.08±4.25⁎
±2.90/11.95±3.85 9.82±3.08/9.70±3.70
±2.87/11.77±3.85 9.57±2.22/9.75±3.78⁎
±2.82/11.87±3.94⁎ 9.32±3.14/9.90±3.74
±2.83/11.72±3.77 9.57±2.19/9.73±3.64
±4.27/11.41±3.44⁎ 9.95±3.87/9.67±3.50
±2.95/11.88±3.84 9.54±2.60/9.77±3.77
–
±5.65/11.50±3.42⁎⁎ 10.98±7.17/9.63±3.12⁎⁎⁎
1.95/11.74±3.73 11.92±5.47/9.68±3.52⁎
–
ined genotype are compared to the combined set of all other
lation (ex.: CC/nCC means that homocyteine values are being
rying CT or TT genotypes).
combination.
652 A.I. Freitas et al.Although LDL values were not statistically different among
patients and the control group, HDL and total cholesterol were
significantly lower in the former group. Plasma total homo-
cysteine levels were significantly higher in cases when compared
with subjects without CAD.
Table 1 also presents the distribution of genotypes for the 2
loci in controls and cases. In contrast to MTHFR677, genotypes
at MTHFR A1298C locus show statistically different distributions
between cases and controls: there is a significant heterogeneity
in the genotype distribution when comparing patients versus
controls, certainly due to an increase in MTHFR1298 AA in CAD
patients (53.02%) compared to healthy subjects (43.53%). While
the prevalence of homozygous 1298CC was similar in both
groups, higher number of heterozygous AC carriers was seen
among controls vs. cases (50.78 vs. 41.28%). The distribution of
both MTHFR mutations among CAD patients and controls with
respect to age groups and gender was investigated, but no
significant results were obtained. All further analyses were also
performed taking into account these population subdivisions
but, since no statistical relevance was obtained, results are not
shown.
Only the group of patients is in Hardy–Weinberg equilibrium
(HWE) at each locus andoverall (Table 2). The control group is not at
HWE at locus MTHFR A1298C (Pb0.005). As expected, both muta-
tions at MTHFR locus show strong significant linkage disequilibrium
(Pb0.00001). Thus taking in consideration the two loci combined,
both populations are significantly different in which concerns the
genic differentiation (χ2df4=11.559, P=0.02).Table 4 Allele, genotype and haplotype association betwee
Allele
MTHFR677 C
T
MTHFR1298 A
C
Genotype
MTHFR677 CC
CT
TT
MTHFR1298 AA
AC
CC
Haplotype
MTHFR 677-1298 C–A
T–A
C–C
T–C
Combined genotype
MTHFR 677-1298 CC–AA
CC–AC
CC–CC
CT–AA
CT–AC
CT–CC
TT–AA
TT–AC
TT–CC b
Values presentation: OR(95% CI); ⁎Pb0.05, ⁎⁎Pb0.005, ⁎⁎⁎Pb0.0001
a for Hcy levelsN15 µmol/l.
b Combined genotype TT–CC was not observed.Individuals with MTHFR 677Tallele showed significantly higher
levels of serum Hcy than those carrying the 677C allele, both in
CAD patients and controls (Table 3). There was a grade increase in
plasma Hcy concentrations from CC to TT genotypes of MTHFR677
polymorphism, both in individuals with and without CAD. For
cases and controls, none of the MTHFR1298 alleles seemed to be
associated with Hcy plasmatic levels, but those subjects
presenting the 1298AA genotype showed significantly higher
values of serum Hcy than those carrying the 1298AC and CC
genotypes. On the other hand, 1298AC heterozygous patients
presented the lowest observed Hcy levels. The haplotype 677T/
1298A was found to be significantly associated with an increase in
Hcy values in cases and controls, while 677C/1298C haplotype
carriers had significantly lower Hcy levels when compared to non
677C/1298C. In controls, the haplotype 677C/1298A also corre-
sponded to significantly lower mean plasmatic Hcy values, when
compared to non 677C/1298A individuals. When combining
genotypes from both polymorphisms, we found that 677CC/
1298AA corresponds to a significant increase in Hcy levels for
both cases and controls, while there was a divergence concerning
the genotype combination corresponding to lower Hcy medium
values: a significant decrease was obtained for the CC/AC com-
bination in cases and CC/AA in controls.
Both the Tallele of MTHFR677 and the A allele of MTHFR1298
showed a significant association with hyperhomocysteinemia but
not with CAD (Table 4). While both 677TT and 1298AA genotypes
were found to be related with hyperhomocysteinemia, only the
1298AA showed significant association with the development ofn MTHFR polymorphisms, hyperhomocysteinemia and CAD
HyperHcy a CAD
NS NS
2.271(1.56–3.30)⁎⁎⁎ NS
1.822(1.14–2.91)⁎ NS
NS NS
NS NS
NS NS
2.862(1.47–5.56)⁎⁎⁎ NS
2.056(1.19–3.54)⁎ 1.476(1.10–1.96)⁎⁎
NS NS
NS NS
NS NS
2.224(1.53–3.24)⁎⁎⁎ 1.241(1.00–1.54)⁎
0.513(0.32–0.83)⁎⁎ 0.798(0.64–1.00)⁎
NS NS
NS NS
0.506(0.26–0.99)⁎ 0.688(0.49–0.96)⁎
NS NS
2.148(1.27–3.64)⁎⁎ 1.558(1.12–2.17)⁎
NS NS
NS NS
3.323(1.70–6.49)⁎⁎ NS
NS NS
– –
, NS not significant PN0.05.
653MTHFR gene, homocysteine and CAD in PortugalCAD. On the other hand, the haplotype associations showed
the same tendencies both for hyperhomocysteinemia and CAD:
the 677T-1298A provided an increased risk, while the 677C-
1298A haplotype corresponded to the lowest significant odds
value. The individuals carrying the combined MTHFR genotype
677CC-1298AC had the lowest risk of hyperhomocysteinemia
and CAD, vs. individuals 677CT-1298AA with the highest risk of
CAD and individuals 677TT-1298AA with the highest risk of
hyperhomocysteinemia.
Multiple logistic regression was used to test for independent
correlates of the presence of CAD. Included in the model were
most of the variants included in Table 1. A Family history of CAD,
arterial hypertension, PWV, Diabetes mellitus, dyslipidaemia and
plasma Hcy (OR=1.149 95% CI: 1.06–1.21, P=0.002) were found
to be independent correlates of the presence of CAD.Discussion
Biochemical and behavioural factors such as arterial
hypertension, dyslipidaemia, diabetes, obesity, ciga-
rette smoking and alcohol ingestion were found to be
significantly different in cases versus controls. Never-
theless, total cholesterol values were lower among
cases, most probably due to the therapy nearly all of
them follow after being diagnosed for CAD. Our study
showed that patients with documented CAD by
angiography had significantly higher levels of Homo-
cysteine (Hcy) than those without CAD. Plasma Hcy
level remained an independent risk factor for CAD,
even after multivariate logistic regression analysis.
These data support a hypothetical connection be-
tween mild hyperhomocysteinemia and CAD. Some
studies support our findings, showing a strong as-
sociation between Hcy and CAD [28]. Others have
reported an elimination of this association after ad-
justing for cardiovascular risk factors claiming that
hyperhomocysteinemia may be an effect of vascular
disease rather than its cause [4,29,30]. Even in the
midst of conflicting data, a consensus emerges con-
sidering mild hyperhomocysteinemia as an indepen-
dent risk factor for cardiovascular disease [1,31].
Few recent studies have tried to compare MTHFR
677 and/or 1298 genotype distributions between
CAD patients and controls, their influence in cir-
culating Hcy, and also the role of hyperhomocystei-
nemia in the aetiology of CAD [32–35]. Different
sample sizes and a different genetic ethnic back-
ground, are probably on the basis of discrepancies
between these studies: all are in agreement with the
association between MTHFR C677T-TT genotype and
higher Hcy plasmatic levels [32–35], but only one
found a significant genotypic association with CAD
[33]. Regarding the A1298C variant, results tend to
greatly disagree: among Moroccans MTHFR 1298 was
found to influence Hcy levels and act as an inde-
pendent risk factor for CAD [34]; but no association
whatsoever with Hcy levels or CAD were found in
Caucasians [35]. Three out of four studies [32–34]obtained a significant and independent association
between HyperHcy and CAD.
Mechanisms by which hyperhomocysteinemia pro-
motes the development of CAD are still not fully
understood. Supposed mechanisms of Hcy induced
atherosclerosis include impaired production of
endothelium-derived nitric oxide, stimulated prolif-
eration of smooth muscle cells, endothelial cell
growth inhibition and effects on platelets and coa-
gulation [36,37]. Increasedproduction of free radicals
may also be involved in Hcy-mediated damage [38].
Several studies have also shown that elevated levels
of this aminoacid may induce DNA damage [39,40].
Hyperhomocysteinemia may result from either gene-
tic or nutritional causes. If a genetic variant in-
fluences the plasma level of a potential causal risk
factor, a similar association would be expected bet-
ween the variant and disease, as between the plasma
level and disease. The most common genetic defects
of Hcy metabolism are two mutations in the gene
encoding for the enzyme MTHFR: MTHFR C677T,
originating a thermolabile form of the enzyme and
MTHFR A1298C. Our results show that the thermo-
labile MTHFR variant has a marked impact on plasma
Hcy level which is significantly higher in the presence
of the T allele and TT genotype. We also found the
same pattern of influence with the A allele and AA
genotype of the 1298 polymorphism. Thus, the
presence of haplotype 677C/1298C resulted in sig-
nificantly lower mean levels of Hcy, while the indi-
viduals with haplotype 677T/1298A showed a
significant increase in plasmatic Hcy. Homozygosity
for the C677T MTHFR mutation has been extensively
associated with intermediate and mild hyperhomo-
cysteinemia [11,41,42], while most studies have
failed to find an association between the MTHFR
A1298C and Hcy levels [43,44].
Despite the clear effect of the thermolabile
variant on elevated tHcy levels, we did not observe
any association between C677Talleles or genotypes
and the risk of CAD in our population. Our study is in
the same line with previous ones in which no
association between C677T variants and angiogra-
phically diagnosed CAD was found [13, 45–47]. It
seems that this polymorphism is only associated with
an increased risk of CAD under low-folate conditions,
varying between different populations according to
characteristic folate intake [14]. On the other hand,
our results show that the 1298AA genotype promotes
a significantly increased risk of CAD. Similar results
were found in a study evolving a Corsica island
population [48]. The 1298A allele association with
CAD provides significance to haplotype and com-
bined genotype association with the disease. The
haplotypes 677T/1298A and 677C/1298C provide the
highest and lowest relative CAD risk, respectively.
654 A.I. Freitas et al.While individuals with 677CT/1298AA genotype
combination have a significant increase in the odds
of becoming CAD patients, 677CC/1298AA corre-
sponds to a significant trend towards a decrease in
CAD incidence.
While our patient subpopulation was in Hardy–
Weinberg equilibrium for A1298C polymorphism of
MTHFR gene, the control subpopulation was not,
due to an excess of heterozygotes AC. Similar results
have previously been reported for other human
genes, including ACE I/D polymorphism, also com-
monly associated with CAD [49,50]. This may be
interpreted as a case of heterosis, or even confirm
the higher risk homozygotes AA face in the devel-
opment of CAD.
In agreement with previous reports, our results
demonstrated that the two variants 677Tand 1298C
are in complete linkage disequilibrium [12,15].
Notably, the combination of a 677TT and 1298CC
genotype did not occur in our population, and
the number of individuals with 677TT/ 1298AC and
677CT/1298CC genotype combinations was very
low. Various studies have also examined the com-
pound genotype distribution of the two MTHFR
polymorphisms, and reported that the 677T and
1298C alleles never or rarely occur in cis config-
uration [15,48,51]. Presumably, the two poly-
morphisms arose separately on different alleles,
and because of the small distance separating them
on the chromosome, little crossing over has oc-
curred. The prevalence of C677T and A1298C poly-
morphisms in neonatal and foetal tissue samples
reported that although the 677TT/1298CC geno-
type was present in foetal tissue samples, it was
absent in the neonatal group [52]. The authors
surmised that this genotype with four mutant
alleles in the MTHFR gene may impair the viability
of the foetus.
Our study made a contribution to the assess-
ment of MTHFR genotype and haplotype influence
on circulating Hcy levels in a Portuguese pop-
ulation, confirming these observations in patients
with angiographic CAD and healthy controls. These
findings suggested that the AA genotype of
MTHFR1298, which can cause a predisposition to
increased plasma Hcy levels, may itself be a ge-
netic risk factor for CAD. On the other hand, the
MTHFR677 gene polymorphism is related to ho-
mocysteine metabolism but does not predict the
risk of CAD as a susceptible genetic marker in our
population.
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